Medication info
Nexgliptin Duo Tablet 50/500 mg

Nexgliptin Duo Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
BNX Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200118 · Approved 2022.01.06 · Insurance code 643105760

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).

Ingredients

Manufacturer
BNX Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulties in blood sugar control
View approved original text

This medication is used along with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be used when it is difficult to control blood sugar levels alone if there is no prior experience with diabetes medication. Additionally, this medicine is used when monotherapy with metformin or sitagliptin is insufficient, or when it is necessary to replace combination therapy with both drugs. If blood sugar is not controlled with combination therapy of metformin with sulfonylurea, or metformin with thiazolidinedione, this medication can be added to enhance blood sugar control. It is also added to improve therapeutic effect in cases where control is difficult with insulin and metformin combination therapy. In summary, this medicine is used to improve blood sugar control in various medication treatment scenarios.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).

Precautions

This medication is a combination product that contains sitagliptin and metformin, and is used for blood sugar control in patients with type 2 diabetes. When taking this medication, serious hypersensitivity reactions can occur, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, stop taking the medication immediately and consult a doctor. Serious pancreatic inflammation known as pancreatitis can occur, so if there are symptoms like abdominal pain, vomiting, or persistent abdominal discomfort, quickly visit a hospital. Furthermore, due to the metformin component, a rare but fatal metabolic disorder called lactic acidosis may occur, so if there is sudden fatigue, muscle pain, difficulty breathing, abdominal pain, severe vomiting, or diarrhea, it is important to inform medical personnel immediately. Patients with severely impaired kidney function, severe infection, dehydration, acute myocardial infarction, sepsis, or acute heart failure should not take this medication, and it should be discontinued before and after tests using iodinated contrast agents. Women who are pregnant or may become pregnant, and those who are breastfeeding, should also not use this medication. While taking this medication, it is crucial to maintain regular meals and proper exercise, and be cautious of symptoms of hypoglycemia if blood sugar decreases too low. The risk of hypoglycemia may be increased, especially when used with other blood sugar-lowering agents. Elderly patients may experience reduced kidney function, therefore regular kidney function tests should be conducted, and dosage adjustment may be necessary. This medication should be used cautiously in patients with impaired liver function, and alcohol consumption should be avoided as it can increase the risk of lactic acidosis. In case of surgery, this medication should be stopped 48 hours prior to the surgery and restarted only after confirming normal kidney function post-surgery. Additionally, this medication may interact with other drugs, so if there are current medications being taken, inform your doctor or pharmacist, especially when used in combination with drugs that may affect kidney function, careful observation of kidney function is required. It is important to regularly monitor blood sugar, kidney function, and blood tests while taking this medication to check health status.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 29 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • elevated liver enzymes
  • acute renal failure
  • dermatitis
  • loss of appetite
  • weight loss
  • neutrophilia
  • increased serum creatinine
  • decreased vitamin B12
  • reduced appetite
  • gastrointestinal disturbances
  • itching
  • dizziness
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that is airtight and kept at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.